Progression-Free Survival Is Adequate Primary Endpoint For Melanoma Trials
Executive Summary
Progression-free survival is an appropriate primary endpoint to support the approval of metastatic melanoma therapies, FDA's Oncologic Drugs Advisory Committee agreed
You may also be interested in...
Aventis, Genta To Meet With FDA After Genasense NDA Withdrawal
Aventis will participate in Genta's meeting with FDA following the withdrawal of the new drug application for Genasense
Aventis, Genta To Meet With FDA After Genasense NDA Withdrawal
Aventis will participate in Genta's meeting with FDA following the withdrawal of the new drug application for Genasense
Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte
Three-year disease-free survival is an adequate endpoint for standard approval of a colorectal cancer agent in the adjuvant setting, FDA's Oncologic Drugs Advisory Committee concluded May 4